Interní Med. 2010; 12(10): 510-515

How to follow patients with oncology disease in a family?

MUDr.Lenka Foretová, Ph.D.
Oddělení epidemiologie a genetiky nádorů, Masarykův onkologický ústav, Brno

Cancer diseases are mostly polyfactorial, but in 5–10 % of cases the disease may be of hereditary origin. Mutations in a high-risk gene are

transmitted from generation to generation and increase the probability of cancer occurrence many times. Genetic examination should

be indicated in families with repeated cancer, especially in young age, with multiple malignancies, with combination of rare cancers. In

families where the disease is probably not hereditary, the prevention in relatives is also important, evaluation of the risk and offering

a preventive care is important. This follow-up of relatives of cancer patients is not routinely done.

Keywords: heredity, tumor diseases, genetic testing

Published: November 15, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Foretová L. How to follow patients with oncology disease in a family? Interní Med. 2010;12(10):510-515.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Foretová L, Macháčková E, Šachlová M, et al. Syndrom familiárního melanomu (s dysplastickými naevy či bez nich). Klin Onkol 2009 (Suppl S1): S32-S33.
    2. Foretová L, Navrátilová M, Macháčková E. Limitace genetického testování v onkologii. Klin Onkol 2009 (Suppl S1): S65-S68.
    3. Garber JE, Offit K. Hereditary cancer predisposition syndromes. J. Clin. Oncol. 2005; 23 (2): 276-292. Go to original source... Go to PubMed...
    4. Goetz P, Foretová L, Puchmajerová A. Hereditární etiologie nádorových onemocnění a význam genetického poradenství a testování v onkologii. Klinická onkologie Suppl, 2006; 19: 44-47.
    5. Křepelová A. Dědičné formy nádorů ledvin - spektrum predispozičních genů a jejich testování. Klinická onkologie Suppl., 2006; 19: 82-84.
    6. Lindor NM, Greene MH. The Mayo Familial Cancer Program: The Concise Handbook of Family Cancer Syndromes. J Natl Cancer Inst. 1998; 90: 1039-1071. Go to original source... Go to PubMed...
    7. Plevová P, Krutílková V, Puchmajerová A, Foretová L. Gorlinův syndrom. Klin Onkol 2009 (Suppl S1): S34-35.
    8. Plevová P, Šilhánová E, Foretová L. Vzácné hereditární syndromy s vyšším rizikem vzniku nádorů. Klinická onkologie Suppl., 2006; 19: 68-75.
    9. Vrtěl R, Filipová H, Vodička R, et al. Tuberosní skleróza. Klin Onkol 2009 (Suppl S1): S50-S53.
    10. Berchuck A, Schildkraut JM, Marks JR, et al. Managing hereditary ovarian cancer risk. Cancer Supplement, 1999; 86: 2517-2524. Go to original source... Go to PubMed...
    11. Ford D, Easton DF, Stratton M, et al. Genetic heterogenity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am. J. Hum. Genet. 1998; 62: 676-689. Go to original source... Go to PubMed...
    12. Plevová P, Novotný J, Petráková K, et al. Syndrom hereditárního karcinomu prsu a ovarií. Klin Onkol 2009 (Suppl S1): S6-S11.
    13. Rebbeck TR. Inherited genetic predisposition in breast cancer. A population-based perspective. Cnacer 1989; 86: 2493-2501. Go to original source...
    14. Zikan M, Foretova L, Cibula D, et al. Hereditary ovarian cancer - Review. Ceska Gynekol. 2006; 71 (3): 246-251.
    15. Zikán M, Jančárková N, Pohlreich P, et al. Hereditární dispozice ke karcinomu prsu a ovaria. Časopis lékařů českých, 2004; 143(1): 26-30. Go to PubMed...
    16. Kleibl Z, Novotny J, Bezdickova D, et al. The CHEK2 c.1100delC germline mutation rarely contributes to breast cancer development in the Czech Republic. Breast Cancer Res Treat. 2005; 90(2): 165-167. Go to original source... Go to PubMed...
    17. Schutte M, Seal S, Barfoot R, et al. Variants in CHEK2 other than 1100delC do not make a major contribution to breast cancer susceptibility. Am. J. Hum. Genet. 2003; 72: 1023-1028. Go to original source... Go to PubMed...
    18. Walsh T, Casadei S, Coats KH, Swisher E, et al. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA 2006; 295(12): 1379-1388. Go to original source... Go to PubMed...
    19. Foretova L, Machackova E, Navratilova M, et al. BRCA1 and BRCA2 mutations in women with familial or early-onset breast/ovarian cancer in the Czech Republic. Human Mutation 2004; 23(4): 397-398. Go to original source... Go to PubMed...
    20. Lukešová M, Macháčková E, Vašíčková P, et al. Výsledky testování BRCA1 a BRCA2 genů v molekulárně genetické laboratoři Masarykova onkologického ústavu. Klinická onkologie Suppl., 2006; 19: 48-54.
    21. Macháčková E, Plevová P, Lukešová M, et al. Genetická predispozice ke vzniku maligního nádoru prsu. Klinická onkologie Suppl., 2006; 19: 48-54.
    22. Vašíčková P, Macháčková E, Lukešová M, et al. Varianty neznámého významu a intragenová přeskupení v genech BRCA1 a BRCA2. Klinická onkologie Suppl., 2006; 19: 58-62.
    23. Bartoňková H, Foretová L, Helmichová E, et al. Doporučené zásady péče o nemocné s nádory prsu a vaječníků a zdravé osoby se zárodečnými mutace genů BRCA1 nebo BRCA2. Klinická onkologie 2003; 16(1): 28-34.
    24. Petráková K, Paláková M, Foretová L. Algoritmus preventivních vyšetření u geneticky podmíněných malignit. Klinická onkologie 2006; 19(Suppl.): 88-90.
    25. Schneiderová M, Bartoňková H. Úloha magnetické rezonance v mammologické prevenci u žen s dědičným rizikem nádoru prsu. Klinická onkologie Suppl., 2006; 19: 91-96.
    26. Warner E, Plewes DB, Shumak RS. Comparison of Breast Magnetic Resonance Imaging, Mammography, and Ultrasound for Surveillance of Women at High Risk for Hereditary Breast Cancer. J Clin Oncol, 2001; 19: 3524-3531. Go to original source... Go to PubMed...
    27. Blanchard DK, Hartmann LC. Prophylactic surgery for women at high risk for breast cancer. Clin Breast Cancer 2000; 1: 127-134. Go to original source... Go to PubMed...
    28. Dražan L. Profylaktická mastektomie a její indikace u rizikových žen. Klinická onkologie Suppl, 2006; 19: 97-100.
    29. Eisen A, Rebbeck TR, Wood WC, et al. Prophylactic Surgery in Women With a Hereditary Predisposition to Breast and Ovarian Cancer 2000; JCO 18: 1980-1995.
    30. Hughes KS, Papa MZ, Whitney T, et al. Prophylactic mastectomy and inherited predisposition to breast carcinoma. Cancer Supplement, 1999; 86: 2502-2515. Go to original source...
    31. Meijers-Heijboer EJ, Verhoog LC, Brekelmans CTM, et al. Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation. Lancet 2000; 355: 2015-2020. Go to original source... Go to PubMed...
    32. Meijers-Heijboer H, van Geel B, van Putten WLJ, et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N. Engl. J. Med. 2001; 345: 159-163. Go to original source... Go to PubMed...
    33. Rebbeck TR, Lynch HT, Neuhausen SL, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002; 346: 1616-1622. Go to original source... Go to PubMed...
    34. Rebbeck TR, Levin AM, Eisen A, et al. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J. Natl. Cancer Inst. 1999; 91: 1475-1479. Go to original source... Go to PubMed...
    35. Grabick DM, Hartmann LC, Cerhan JR, et al. Risk of breast cancer with oral contraceptive use in women with family history of breast cancer. JAMA 2000; 284: 1791-1798. Go to original source... Go to PubMed...
    36. Modan B, Hartge P, Hirsh-Yechezkel G, et al. Parity, Oral Contraceptives, and the Risk of Ovarian Cancer among Carriers and Noncarriers of a BRCA1 or BRCA2 Mutation. N Engl J Med 2001; 345: 235-240. Go to original source... Go to PubMed...
    37. Narod SA, Risch H, Moslehi R, et al. Oral Contraceptives and the Risk of Hereditary Ovarian Cancer. N Engl J Med 1998; 339: 424-428. Go to original source... Go to PubMed...
    38. Ursin G, Henderson BE, Haile WR, et al. Does oral contraceptive use increase the risk of breast cancer in women with BRCA1/BRCA2 mutations more than in other women? Cancer Res, 1997; 57: 3678-3681.
    39. Fisher B, Constantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl. Cancer Inst. 1999; 90: 1371-1388. Go to original source... Go to PubMed...
    40. King MC, Wieand S, Hale K. Tamoxifen use reduces breast cancer risk in BRCA2 positive women. JAMA, 2001; 286: 2251-2256. Go to original source... Go to PubMed...
    41. Kinzler K, Vogelstein B. Cancer-susceptibility genes: gatekeepers and caretakers. Nature, 1997; 386: 761-762. Go to original source... Go to PubMed...
    42. Kinzler K, Vogestein B. Lessons from hereditary colorectal cancer. Cell 1996; 87: 159-170. Go to original source... Go to PubMed...
    43. Ivanovich JL, Reed TE, Ciske DJ, et al. A practical approach to familial and hereditary colorectal cancer. Am. J. Med., 1999; 107: 68-77. Go to original source... Go to PubMed...
    44. Plevová P, Novotný J, Šachlová M, et al. Hereditární nepolypózní kolorektální karcinom (HNPCC, Lynchův syndrom). Klin Onkol 2009 (Suppl S1): S12-S15.
    45. Křepelová A, Pavlíková K, Plevová P. Diagnostika Lynchova syndromu - nové geny a metody. Klinická onkologie Suppl., 2006; 19: 76-81.
    46. Lynch HT, de la Chapelle A. Genetic susceptibility to non-polyposis colorectal cancer. J. Med. Genet. 1999; 36: 801-818.
    47. Lynch HT, Lynch J. Lynch syndrome: genetics, natural history, genetic counseling, and prevention. J. Clin. Oncol. Supplement, 2000; 18: 19-31.
    48. Lynch HT, Chapelle A. Hereditary colorectal cancer. New England Journal of Medicine 2003; 348: 919-932. Go to original source... Go to PubMed...
    49. Fearnhead NS, Britton MP, Bodmer WF. The ABC of APC. Human Molecular Genetics 2001; 10: 721-733. Go to original source... Go to PubMed...
    50. Foretova L, Skricka T. Psychosocial and medico-legal aspects of genetic counseling in familial adenomatous polyposis. Chapter 21 in Intestinal Polyps and Polyposis. Delaini GG, Skricka T, Colucci G, et al. Springer 2009. Go to original source...
    51. Plevová P, Štekrová J, Kohoutová M, et al. Familiární adenomatózní polypóza. Klin Onkol 2009 (Suppl S1): S16-S19.
    52. Sampson JR, Dolwani S, Jones S, et al. Autosomal recessive colorectal adenomatous polyposis due to inherited mutations of MYH. Lancet 2003; 362: 39-41. Go to original source... Go to PubMed...
    53. Štekrová J, Šulová M, Zídková K, et al. Familiární adenomatosní polypóza - novinky v molekulární diagnostice. Klinická onkologie Suppl. 2006; 19: 63-67.
    54. Eng C.PTEN: one gene, many syndromes. Human Mutation 2003; 22: 183-198. Go to original source... Go to PubMed...
    55. Giardiello FM, Brensinger JD, Tersmette AC, et al. Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology 2000; 119: 1447-1453. Go to original source... Go to PubMed...
    56. Ivanovich JF, Whelan AJ. Cancer and Peutz-Jeghers Syndrome: a Review. Journal of Genetic Counseling, 1997; 6(2): 193-206. Go to original source... Go to PubMed...
    57. Foretová L, Navrátilová M, Petráková K, et al. Kasuistiky Li-Fraumeni syndromu: diagnostické a preventivní možnosti. Klinická onkologie Suppl. 2006; 19: 85-87.
    58. Hisada M, Garber JE, Fung CY, et al. Multiple primary cancers in families with Li-Fraumeni syndrome. J. Natl. Cancer Inst., 1998; 90: 606-611. Go to original source... Go to PubMed...
    59. Krutílková V, Trková M, Kodet R, et al. Syndrom Li-Fraumeni.Čs pediatrie 2003; 58(9): 552-555.
    60. Plevová P, Krutílková V, Petráková K, et al. Syndrom LiFraumeni. Klin Onkol 2009 (Suppl S1): S20-S22.
    61. Trkova M, Foretova L, Kodet R, et al. A Li-Fraumeni syndrome family with retained heterozygosity for a germline TP53 mutation in two tumors. Cancer Genetics and Cytogenetics 2003; 145: 60-64. Go to original source... Go to PubMed...
    62. Varley JM, Evans DGR, Birch JM.: Li-Fraumeni syndrome - a molecular and clinical review. British Journal of Cancer, 1997; 76(1): 1-14. Go to original source... Go to PubMed...
    63. Liaw D, Marsh D, Li J, et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat. Genet. 1996; 16: 64-67. Go to original source... Go to PubMed...
    64. Maher ER, Kaelin WG. Reviews in molecular genetics-von Hippel Lindau disease. Medicine 1997; 76: 381-391. Go to original source... Go to PubMed...

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.